---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-24-000003"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:58:22.450941+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Amneal reaffirms FY2023 guidance: revenue $2.37-2.42B, adj. EBITDA $540-550M

## Summary
- Reaffirmed 2023 guidance previously issued on Nov 7, 2023 at an investor conference on Jan 10, 2024.
- Net revenue range $2.37-$2.42 billion; adjusted EBITDA $540-$550 million.
- Adjusted diluted EPS $0.51-$0.58; operating cash flow $250-$280 million.
- Capital expenditures $50-$60 million; weighted average diluted shares ~310 million.
- Guidance includes 100% of AvKARE Adjusted EBITDA and 35% non-controlling interest in EPS.

## SEC filing metadata
- accession: 0001723128-24-000003
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000003/0001723128-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000003/amrx-20240110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-24-000003
- JSON: https://secwatch.observer/filing/0001723128-24-000003.json
- Plain text: https://secwatch.observer/filing/0001723128-24-000003.txt

## Key facts
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported year ended December 31, 2023 results: revenue $2.37 billion - $2.42 billion, EPS $0.51 - $0.58. Guidance reaffirmed.
  - Period: year ended December 31, 2023
  - Revenue: $2.37 billion - $2.42 billion
  - EPS: $0.51 - $0.58
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Amneal Pharmaceuticals, Inc., a Delaware corporation (the "Company"), reaffirmed guidance with respect to the year ended December 31, 2023, which was previously announced on November 7, 2023 in connection with announcing the Company's third quarter 2023 results: Net revenue $2.37 billion - $2.42 billion Adjusted EBITDA (1) $540 million - $550 million Adjusted diluted EPS (2) $0.51 - $0.58 Operating cash flow (3) $250 million - $280 million Capital expenditures $50 million - $60 million Weighted average diluted shares outstanding (4) Approximately 310 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000003/0001723128-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.